Varnimcabtagene autoleucel for adults with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia in Spain (CART19-BE-02): a multicentre, single-arm, phase 2 trial
Por:
Ortiz-Maldonado, V, Martinez-Cibrian, N, Alserawan, L, Español-Rego, M, Navarro-Velázquez, S, Albiol, N, Oliver-Caldés, A, Triguero, A, Herrero-Garcia, M, Gutiérrez-Herrero, S, Benitez-Ribas, D, Paciello, ML, Torrent, A, Delgado-Serrano, J, Sánchez-Castañón, M, Calderón, H, Mata, JJ, Sánchez-Salinas, A, Sáez-Peñataro, J, Sans-Pola, C, Calvo-Orteu, M, López-Corral, L, Kwon, M, Rifón, J, Charry, P, Alonso-Fernández, RA, Huguet, M, Blázquez-Goñi, C, Sánchez-Pina, JM, Sánchez, R, Rosa-Rosa, JM, Martinez-López, J, Blanquer, M, Ribera, JM, Urbano-Ispizua, A, Bachiller, M, Palau, L, Olesti, E, Calvo, G, Martin-Martin, L, Orfao, A, González-Navarro, EA, Domenech, G, Varea, S, Juan, ME, Delgado, J and Esteve, J
Publicada:
1 mar 2026
Resumen:
Background Varnimcabtagene autoleucel (var-cel) is an autologous CD19-directed chimeric antigen receptor (CAR) T-cell therapy with adaptive intra-patient dose escalation and was approved in Spain in 2021 for patients older than 25 years with relapsed or refractory B-cell precursor acute lymphoblastic leukaemia. We report activity and safety from var-cel's pivotal trial in this patient population. Methods This multicentre, single-arm, phase 2 trial was conducted at nine academic centres in Spain. Eligible patients had CD19+ B-cell precursor acute lymphoblastic leukaemia in the first relapse or refractory disease, either ineligible for allogeneic haematopoietic cell transplantation (HCT) or with relapsed disease after allogeneic HCT; centralised measurable disease in peripheral blood or bone marrow, or both, using flow cytometry; were aged 18-70 years; and had an Eastern Cooperative Oncology Group performance status of 0-2. Patients received a single course of intravenous lymphodepleting chemotherapy with fludarabine (30 mg/m2 per day for 3 days) plus cyclophosphamide (300 mg/m2 per day for 3 days), followed by intravenous fractionated var-cel escalation (0 & centerdot;1, 0 & centerdot;3, 0 & centerdot;6, and 2 & centerdot;0 & times; 106 CART cells per kg) separated by at least 24 h, with each fraction contingent on safety criteria. The primary endpoint was complete response with undetected measurable residual disease (MRD; sensitivity of <= 10-5) determined by flow cytometry by day 28 from var-cel administration, assessed in the efficacy population (defined as all patients who received at least one var-cel fraction). Safety was analysed in patients that initiated lymphodepletion. This study is registered with ClinicalTrials.gov, NCT04778579 (completed). Findings Between May 19, 2021, and July 6, 2023, 50 patients were assessed for eligibility, 12 were ineligible, and 38 were enrolled. 37 (97%) of 38 underwent leukapheresis (ITT population), 33 (87%) initiated lymphodepleting chemotherapy (safety population), and 32 (84%) received at least one var-cel fraction (efficacy population). Five patients who underwent leukapheresis did not receive var-cel due to rapid disease progression (n=3), death due to venooclusive disease (n=1), and persistent COVID-19 (n=1). Patients receiving var-cel had a median age of 40 years (33-48); of whom, 16 (50%) were female and 16 (50%) were male. By data cutoff (Jan 18, 2024), the median follow-up from infusion was 8 & centerdot;6 months (IQR 5 & centerdot;1-14 & centerdot;4) and 27 (84 & centerdot;4% [95% CI 67 & centerdot;2-94 & centerdot;7]) of 32 patients who received at least one dose of var-cel had a complete response with undetected MRD by day 28. Treatment-emergent adverse events occurred in 31 (94%) of 33 patients. The most common grade 3 or higher adverse events were neutropenia in 15 (45%) patients, thrombocytopenia in seven (21%), anaemia in five (15%), and cytokine release syndrome in four (12%). Immune effector cell-associated neurotoxicity syndrome and cerebral oedema was observed in one patient (3%; grade >= 3), and immune effector cell-associated hemophagocytic lymphohistiocytosis-like syndrome occurred in two (6%; one resulted in death after protocol violation due to infusion during uncontrolled sepsis).
Interpretation Var-cel induced deep remissions with low incidence of severe cytokine release syndrome and any-grade immune effector cell-associated neurotoxicity syndrome, supporting fractionated dose escalation as a strategy that preserves activity, limits acute toxic effects, and supports a hospital-based approach that could expand access to CAR T-cell therapy.
Filiaciones:
Ortiz-Maldonado, V:
Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Martinez-Cibrian, N:
Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Alserawan, L:
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Español-Rego, M:
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Navarro-Velázquez, S:
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Albiol, N:
Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Oliver-Caldés, A:
Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain
Herrero-Garcia, M:
Univ Salamanca, Ctr Invest Canc, Salamanca, Spain
Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain
Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain
Univ Salamanca, Inst Biomed Res Salamanca, Canc Res Ctr, Salamanca, Spain
Univ Salamanca, Dept Med, Salamanca, Spain
Gutiérrez-Herrero, S:
Univ Salamanca, Ctr Invest Canc, Salamanca, Spain
Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain
Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain
Univ Salamanca, Inst Biomed Res Salamanca, Canc Res Ctr, Salamanca, Spain
Univ Salamanca, Dept Med, Salamanca, Spain
Benitez-Ribas, D:
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Paciello, ML:
Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain
Torrent, A:
Hosp Germans Trias i Pujol, Inst Oncol Badalona, Dept Clin Haematol, Badalona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Delgado-Serrano, J:
Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain
Univ Seville, Consejo Super Invest Cient, Dept Hematol, Inst Biomed Sevilla,Univ Hosp Virgen del Rocio, Seville, Spain
Sánchez-Castañón, M:
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Calderón, H:
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Mata, JJ:
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Sánchez-Salinas, A:
Hosp Clin Univ Virgen de la Arrixaca, Dept Haematol, Inst Murciano Invest Biosanitaria Pascual Parrilla, Murcia, Spain
Sáez-Peñataro, J:
Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Sans-Pola, C:
Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Calvo-Orteu, M:
Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
López-Corral, L:
Univ Salamanca, Ctr Invest Canc, Salamanca, Spain
Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain
Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain
Univ Salamanca, Dept Med, Salamanca, Spain
Hosp Univ Salamanca, Dept Haematol, Salamanca, Spain
Kwon, M:
Hosp Gen Univ Gregorio Maranon, Dept Hematol, Madrid, Spain
Univ Complutense Madrid, Gregorio Maranon Hlth Res Inst, Madrid, Spain
Rifón, J:
Clin Univ Navarra, Dept Haematol, Pamplona, Spain
Charry, P:
Hosp Clin Barcelona, Dept Haemotherapy & Haemostasis, Barcelona, Spain
Alonso-Fernández, RA:
Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain
Huguet, M:
Hosp Germans Trias i Pujol, Inst Oncol Badalona, Dept Clin Haematol, Badalona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Blázquez-Goñi, C:
Univ Seville, Consejo Super Invest Cient, Dept Hematol, Inst Biomed Sevilla,Univ Hosp Virgen del Rocio, Seville, Spain
Sánchez-Pina, JM:
Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain
Sánchez, R:
Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain
Rosa-Rosa, JM:
Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain
Martinez-López, J:
Univ Complutense Madrid, Hosp Univ 12 Octubre, Inst Invest Hosp 12 Octubre, Dept Haematol, Madrid, Spain
Blanquer, M:
Hosp Clin Univ Virgen de la Arrixaca, Dept Haematol, Inst Murciano Invest Biosanitaria Pascual Parrilla, Murcia, Spain
:
Hosp Germans Trias i Pujol, Inst Oncol Badalona, Dept Clin Haematol, Badalona, Spain
Univ Autonoma Barcelona, Barcelona, Spain
Josep Carreras Res Inst, Barcelona, Spain
Urbano-Ispizua, A:
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Josep Carreras Res Inst, Barcelona, Spain
Bachiller, M:
Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Palau, L:
Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain
Olesti, E:
Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Calvo, G:
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Martin-Martin, L:
Univ Salamanca, Ctr Invest Canc, Salamanca, Spain
Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain
Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain
Univ Salamanca, Inst Biomed Res Salamanca, Canc Res Ctr, Salamanca, Spain
Univ Salamanca, Dept Med, Salamanca, Spain
Carlos III Hlth Inst, Madrid, Spain
Orfao, A:
Univ Salamanca, Ctr Invest Canc, Salamanca, Spain
Univ Salamanca, Inst Biol Mol & Celular Canc, Salamanca, Spain
Univ Salamanca, Consejo Super Invest Cient, Salamanca, Spain
Univ Salamanca, Inst Biomed Res Salamanca, Canc Res Ctr, Salamanca, Spain
Univ Salamanca, Dept Med, Salamanca, Spain
Carlos III Hlth Inst, Madrid, Spain
González-Navarro, EA:
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Domenech, G:
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Med Stat Core Facil, Barcelona, Spain
Varea, S:
Hosp Clin Barcelona, Dept Clin Pharmacol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Juan, ME:
Hosp Clin Barcelona, Dept Immunol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Delgado, J:
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Esteve, J:
Hosp Clin Barcelona, Dept Haematol, Barcelona, Spain
Inst Invest Biomed August Pi i Sunyer, Fundacio Recerca Clin Barcelona, Barcelona, Spain
Univ Barcelona, Barcelona, Spain
Josep Carreras Res Inst, Barcelona, Spain
|